Summit Therapeutics Inc. SMMT

SMMT Quotes by TradingView
Institutional shares held 86.8 Million
1.84M calls
3.13M puts
Total value of holdings $1.72B
$36.5M calls
$62M puts
Market Cap $3.99B
201,215,008 Shares Out.
Institutional ownership 43.16%
# of Institutions 236

Quarterly Institutional Activity in SMMT

Shares Bought
Shares Sold
View Transactions

Top Institutions Holding SMMT

View all
View all

Latest Institutional Activity in SMMT

Top Purchases

Q1 2025
Balyasny Asset Management LLC Shares Held: 1.7M ($33.8M)
1.32M Shares purchased
339.82% Added
Q1 2025
Pictet Asset Management Holding Sa Shares Held: 2.66M ($52.8M)
1.27M Shares purchased
91.86% Added
Q1 2025
Citadel Advisors LLC Shares Held: 999K ($19.8M)
811K Shares purchased
432.93% Added
Q1 2025
Siren, L.L.C. Shares Held: 695K ($13.8M)
695K Shares purchased
New Holding
Q1 2025
Adage Capital Partners Gp, L.L.C. Shares Held: 538K ($10.7M)
538K Shares purchased
New Holding
View All Buyers

Top Sells

Q1 2025
Millennium Management LLC Shares Held: 887K ($17.6M)
1.16M Shares sold
56.73% Reduced
Q1 2025
State Street Corp Shares Held: 4.85M ($96.2M)
752K Shares sold
13.41% Reduced
Q1 2025
Group One Trading, L.P. Shares Held: 0 ($0)
223K Shares sold
Closed
Q1 2025
Twin Tree Management, LP Shares Held: 339K ($6.72M)
157K Shares sold
31.61% Reduced
Q1 2025
Bellevue Group Ag Shares Held: 67.7K ($1.34M)
103K Shares sold
60.32% Reduced
View All Sellers

About SMMT

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.

SMMT Chart by TradingView
SMMT Fundamental Data by TradingView

Insider Transactions at SMMT

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
May 30 2025
Maky Zanganeh Co-Chief Executive Officer
BUY
Exercise of conversion of derivative security
Indirect
74,545 +0.01%
$149,090 $2.64 P/Share
May 30 2025
Robert W Duggan Co-Chief Executive Officer
BUY
Exercise of conversion of derivative security
Direct
74,545 +0.01%
$149,090 $2.64 P/Share
Apr 08 2025
Maky Zanganeh Co-Chief Executive Officer
BUY
Exercise of in-the-money or at-the-money derivatives securities
Indirect
3,985,055 +0.71%
$3,985,055 $1.58 P/Share
Apr 08 2025
Robert W Duggan Co-Chief Executive Officer
BUY
Exercise of in-the-money or at-the-money derivatives securities
Direct
3,985,055 +0.71%
$3,985,055 $1.58 P/Share
Oct 03 2024
Maky Zanganeh Co-Chief Executive Officer
BUY
Exercise of in-the-money or at-the-money derivatives securities
Indirect
315,681 +3.0%
$315,681 $1.58 P/Share
Sep 11 2024
Maky Zanganeh Co-Chief Executive Officer
BUY
Grant, award, or other acquisition
Indirect
44,052 +0.18%
$969,144 $22.7 P/Share
Sep 11 2024
Robert W Duggan Co-Chief Executive Officer
BUY
Grant, award, or other acquisition
Direct
3,325,991 +0.6%
$73,171,802 $22.7 P/Share
Sep 11 2024
Jeff Huber Director
BUY
Grant, award, or other acquisition
Indirect
44,052 +50.0%
$969,144 $22.7 P/Share
Sep 11 2024
Bhaskar Anand Chief Accounting Officer
BUY
Grant, award, or other acquisition
Direct
22,026 +14.35%
$484,572 $22.7 P/Share
Sep 11 2024
Manmeet Singh Soni COO and CFO
BUY
Grant, award, or other acquisition
Direct
44,052 +1.44%
$969,144 $22.7 P/Share
Mar 27 2024
Maky Zanganeh Co-Chief Executive Officer
BUY
Open market or private purchase
Direct
26,000 +4.75%
$78,000 $3.72 P/Share
Mar 26 2024
Ankur Dhingra Chief Financial Officer
BUY
Open market or private purchase
Indirect
100,000 +21.98%
$300,000 $3.75 P/Share
Mar 26 2024
Maky Zanganeh Co-Chief Executive Officer
BUY
Open market or private purchase
Indirect
30,000 +50.0%
$90,000 $3.75 P/Share
Dec 13 2023
Ankur Dhingra Chief Financial Officer
BUY
Open market or private purchase
Indirect
20,400 +3.73%
$40,800 $2.16 P/Share
Dec 12 2023
Maky Zanganeh Co-Chief Executive Officer
BUY
Open market or private purchase
Direct
5,000 +1.0%
$10,000 $2.07 P/Share
Dec 11 2023
Maky Zanganeh Co-Chief Executive Officer
BUY
Exercise of in-the-money or at-the-money derivatives securities
Indirect
315,681 +1.25%
$315,681 $1.58 P/Share
Dec 11 2023
Maky Zanganeh Co-Chief Executive Officer
BUY
Exercise of in-the-money or at-the-money derivatives securities
Direct
489,814 +50.0%
$489,814 $1.44 P/Share
Oct 13 2023
Manmeet Singh Soni COO and CFO
BUY
Open market or private purchase
Direct
2,976,190 +50.0%
$2,976,190 $1.68 P/Share
Mar 08 2023
Maky Zanganeh Co-Chief Executive Officer
BUY
Open market or private purchase
Indirect
7,553,301 +40.57%
$7,553,301 $1.05 P/Share
View All Transactions

Last 12 Months Summary

Buy / Acquisition
11.9M Shares
From 9 Insiders
Grant, award, or other acquisition 3.48M shares
Exercise of conversion of derivative security 149K shares
Exercise of in-the-money or at-the-money derivatives securities 8.29M shares
Sell / Disposition
0 Shares
From 0 Insiders

Track Institutional and Insider Activities on SMMT

Follow Summit Therapeutics Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SMMT shares.

Notify only if

Insider Trading

Get notified when an Summit Therapeutics Inc. insider buys or sells SMMT shares.

Notify only if

News

Receive news related to Summit Therapeutics Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on SMMT